SL
PTGX icon

Salomon & Ludwin’s Protagonist Therapeutics PTGX Stock Holding History

Salomon & Ludwin’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$61.7K Buy
595
+159
+36% +$14.1K 0.01% 397
2025
Q4 		$36.7K Sell
436
-6
-1% -$491 ﹤0.01% 511
2025
Q3 		$28.7K Buy
+442
New +$25.1K ﹤0.01% 607

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Salomon & Ludwin's PTGX Position: Q1 2026 in Review

Salomon & Ludwin increased its Protagonist Therapeutics (PTGX) stake by 36% in Q1 2026, buying an estimated $14.1K and bringing the position to 595 shares worth $61.7K. The position accounts for 0.01% of the portfolio, ranked #397.

Salomon & Ludwin first reported a position in PTGX in Q3 2025 and has held it in 3 quarters since. 317 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

  • Salomon & Ludwin held 595 shares of Protagonist Therapeutics worth $61.7K as of Q1 2026.
  • Salomon & Ludwin bought 159 Protagonist Therapeutics shares in Q1 2026, an estimated $14.1K.
  • Protagonist Therapeutics made up 0.01% of Salomon & Ludwin's portfolio in Q1 2026, its #397 holding.
  • Salomon & Ludwin first reported a position in Protagonist Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 317 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on Salomon & Ludwin's 13F filing for Q1 2026, filed 11 May 2026.